Cipla enters into partnership with Eli Lilly

08 Jun 2018 Evaluate

Cipla has entered into partnership with Eli Lilly and Company (India), a 100% subsidiary of Eli Lilly and Company, a global multinational pharmaceutical leader. Under this agreement, Lilly’s Basaglar that is manufactured by Lilly will be marketed and distributed in India by Cipla. Basaglar is a once-daily insulin glargine therapy for the treatment of patients with type 1 & 2 diabetes above two years of age.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. The company’s portfolio includes over 1500 products across wide range of therapeutic categories with one quality standard globally.

Cipla Share Price

1466.05 -0.10 (-0.01%)
12-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1736.85
Dr. Reddys Lab 1215.65
Cipla 1466.05
Zydus Lifesciences 895.00
Lupin 2189.75
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×